Home/Prelude Therapeutics/David B. Donabedian, Ph.D.

DB

David B. Donabedian, Ph.D.

Chief Scientific Officer

Prelude Therapeutics

Therapeutic Areas

Prelude Therapeutics Pipeline

Drug	Indication	Phase
PRT3789	SMARCA4-deficient tumors (e.g., NSCLC, other solid tumors)	Phase 1/2
PRT2527	Hematologic malignancies (CLL, NHL) and solid tumors	Phase 1
PRT3645	Advanced or metastatic solid tumors	Phase 1
PRT7732	Advanced solid tumors and hematologic malignancies	Preclinical

Leadership Team at Prelude Therapeutics

Krishna Vaddi, Ph.D.

Chief Executive Officer, President, and Founder

David J. Wurzer

Chief Financial Officer and Treasurer

David B. Roth, M.D., Ph.D.

Chief Medical Officer

Paul M. McBarron

Chief Operating Officer

Martin D. Williams

Chairman of the Board of Directors

John E. Goddard, Ph.D.

Laurie B. Keating

John H. Lee, M.D., Ph.D.

View full Prelude Therapeutics profile